Added. Can't resist with such a stupid fall with the general mkt |
Maintained divi despite 1.8 billion payout for Zantac from existing resources. Medicines pipeline away from vaccines-for which GSK is now one of the leading big pharma producers worldwide-better than it has been for years. Good position for substantial future divi play. |
Great results |
GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases. |
TM - I, too, was thinking of the former. |
 "It would be interesting to read why they chose this site over other options."
Alphorn - could have been planned as a massive hedge to curry favour with the US authorities in case the Zantac litigation went wrong ....
Or a connection to:
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
This public-private agreement marks the first time that HHS has taken a “portfolio approach” to funding drug development with a private sector company. This unique collaboration provides flexibility to move funding around GSK’s antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens.
Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to a total of $200 million if the agreement is renewed over five years. |
Blame the Labour government. |
It would be interesting to read why they chose this site over other options. May well be fiscal deductions against the huge US income?
edit: a bit more - worth a read. |
GSK will invest up to $800 million at its site in Marietta, Pennsylvania to create new facilities dedicated to producing medicines and vaccines, doubling its capacity. The expansion is expected to create 200 jobs.
Regis Simard, GSK's president for global supply chain, said the investment "will establish Marietta as an innovation and manufacturing hub capable of delivering next-generation medicines and vaccines." Since 2017, the drug maker has invested nearly $1.3 billion in its US production capabilities.
The pharma noted that the new facility will be able to manufacture sterile liquid vaccines and medicines, whilst also housing an R&D pilot plant to manufacture drugs for clinical trials. In addition, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company's MAPS technology.
Construction at Marietta is expected to start by the end of this year. The drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility online by the end of the following year. |
https://www.proactiveinvestors.co.uk/companies/news/1059160/gsk-looking-to-move-on-from-zantac-litigation-1059160.html |
This might end blue today |
 Big investors have little real confidence in Emma imo. For such an important UK bellwether GSK needs a CEO who is promoting the company, out there, getting IIs on board. Look at how protective the French Government is of their companies like Sanofi.
Despite a string of small positive RNSs over the past two years-none of which are mega, but incrementally should be driving the bottom line and dividend increases, which is what GSK is all about, we hear little. Emma is not pushing hard enough-or just seems to lack the authority (unlike Pascal Soirot at AZN) to gain the markets respect.
No mainstream publicity whatsoever regarding the latest filling for treating UTIs. While these things do not bring the recurring revenue of Statins etc they can have a profound impact on the lives of many women with recurring infections and a rare, new antibiotic is significant and should be news. Where is the marketing-although it's still awaiting the FDAs approval-which could at least bolster GSK's profile for trying? |
Based on 12 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is 1,708.00p with a high forecast of 2,000.00p and a low forecast of 1,500.00p. The average price target represents a 17.37% change from the last price of 1,455.25p. |
Some US analyst reporting they expect to see a drop in earnings at the GSK 30th update, we will soon see what we get, and the next dividend (15 pence)..
Possibly the reason for the dip this morning... |
Yes I agree - ‘post’ Zantac I would have expected to see some improvement in the share price Fresh ideas required imo.
Suet |
Emma needs to go |
New data for Arexvy, GSK's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
· Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD
· Two doses of vaccine in immunocompromised adults aged 18 and above elicited immune responses similar to one dose in healthy adults aged 50+ and with an acceptable safety profile
· In the US alone, adults aged 18-49 with at least one risk factor for RSV disease could exceed 21 million |
I'm invested so I think it can turn around. There is some promise and focus in the pipeline. If they did anything suicidal like increase the dividend I would be out immediately.
Different sector, but SSE has significantly improved its performance since it rebased its dividend, twice. Not only that but my tax bill on reinvesting has also halved. Dividend reinvestment is an absolutely insane concept really, just keep the money inside the company, job done. Spit out 1 or 2% so investors can cover costs, no more. |
So do we take the view that GSK will continue to underperform and go elsewhere, or believe that the worm will turn here eventually? Whilst it's very frustrating being in this I'm still sticking with the latter. |
GSK has fallen dramatically in the global table in recent years; GW+SKB may have accelerated this decline. |
It is the comparison with AZN which is stark. It pays out much less, always has, but is a 2-bagger over 10 years, without reinvesting dividends. Pharma investors need to understand that as a business it is no different to a mining, company, oil company, for that matter any trading company; there is no infinite pipeline of revenue, assets have to be renewed all the time. |
I prefer to focus on the consequences rather than historic treatments which do not always recognise business trends. |
Well if you really want to know, accounting standards IAS38 (International) and SSAP13 (UK) deal with the accounting treatment of R&D. |
A complex subject. Pharma A carries out R&D and reports a cost. Pharma B buys in third party R&D and puts it on its Balance Sheet and is free to pay whatever dividends. Which is GSK? |
Paying excess dividends is what put GSK into its no growth situation...
I'd say rather that having no growth is what put GSK into its no growth situation, not excess divis. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
